Παρασκευή 18 Δεκεμβρίου 2015

PROSPECTIVE PHASE II TRIAL OF TRABECTEDIN IN BRCA MUTATED AND/OR BRCAness PHENOTYPE RECURRENT OVARIAN CANCER PATIENTS: THE MITO 15 TRIAL

Trabectedin is particularly active in heavily pretreated, BRCA mutated and/or BRCAness phenotype recurrent ovarian cancer patients. Toxicity profile appear in line with what reported in literature. Trabectedin may represent a valuable option in recurrent platinum sensitive ovarian cancer patients, not willing to receive or not able to receive further platinum-based treatments. In platinum resistant BRCA mutated and/or BRCAness phenotype patients the activity of the drug appears of particular interest and merits further evaluation.



from Cancer via ola Kala on Inoreader http://ift.tt/1Idxnsw
via IFTTT

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου